Results and News

The 4th edition of The promises of Treg and Interleukin-2 therapies will take place 21–24 October 2026 at the International Conference Center, Sorbonne University in Paris. Registration is open. https://www.il2-2026.com/ Many key opinion leaders have already confirmed their participation as speakers. Stay informed by checking our official website for the latest updates!

The annual TiilT project meeting was successfully organized in Trieste, bringing together representatives from all project partners for a two-day meeting dedicated to reviewing progress, discussing achievements, and planning the next steps of the project. The meeting provided a valuable opportunity for partners to exchange updates on the different work packages, address ongoing challenges, and strengthen collaboration within the consortium. Through fruitful scientific and tec

Paris, France – May 10, 2025 – ILTOO Pharma is pleased to welcome the publication in The Lancet of the results from the MIROCALS phase IIb clinical trial ( Access the MIROCALS Trial article in The Lancet ) shows that low-dose interleukin-2 (IL-2 LD ), a therapy pioneered by ILTOO Pharma, significantly improves survival and slows functional decline in patients with Amyotrophic Lateral Sclerosis (ALS), a fatal neurological disease with limited therapeutic options. The study,

The research group led by Serena Zacchigna at the University of Trieste has found a new way of improving gene therapy for cardiovascular diseases by enhancing the efficiency of gene transfer to cardiac endothelial cells. They found that endothelial to mesenchymal transition (EndMT), which happens spontaneously in many pathological conditions, significantly boosts AAV transduction. These results, published in November 2024 in Molecular Therapy, offers new opportunities to driv

The IVORY study, conducted with the involvement of Ziad Mallat from Inserm, explored the therapeutic potential of low-dose interleukin-2 to reduce arterial inflammation in patients with acute coronary syndrome. The study demonstrated a 7.7% reduction in arterial inflammation, along with a favorable safety profile, and indicated a potential reduction in major adverse cardiovascular events. The results were presented at the ESC Congress 2024 in London.

The 2024 edition of "The Promise of Interleukin-2 Therapy" chaired by David Klatzmann (TiilT project coordinator), concluded successfully in Paris after four days of engaging scientific exchange, held from September 4 to 7 . With over 300 participants from around the globe, the event reaffirmed its status as a landmark event in the field of IL-2 research and immunotherapy. This year’s program offered a comprehensive exploration of IL-2 , covering topics that ranged from

The team led by Roger Legrand at IDMIT is pleased to share two key developments that mark significant progress in our research and strategic positioning within major national programs. - In Vivo Imaging of CD8+ T Cells: Proof of Concept for TiiLT Technologies The recent publication by De Groof et al. , focusing on the in vivo imaging of CD8+ T cells , showcases a promising advancement in immunological imaging. Although this study was not formally funded by the Tii